Prognostic value of preoperative diabetes mellitus in patients with non-functional pancreatic neuroendocrine neoplasms

被引:4
|
作者
Tan, Qingquan [1 ]
Wang, Xing [1 ]
Chen, Chen [2 ]
Liu, Xubao [1 ]
Chen, Yonghua [1 ,3 ]
Tan, Chunlu [1 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Pancreat Surg, Chengdu, Sichuan, Peoples R China
[2] First Peoples Hosp Chengdu, Dept Radiol, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pancreat Surg, 37 Guo Xue Alley, Chengdu 610041, Sichuan, Peoples R China
来源
AMERICAN JOURNAL OF SURGERY | 2022年 / 224卷 / 04期
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
Pancreatic neuroendocrine neoplasms; Prognosis; Diabetes mellitus; New-onset diabetes; Impaired fasting glucose; POPULATION-BASED ANALYSIS; RISK-FACTORS; CANCER; TUMORS; SURVIVAL; GLUCOSE;
D O I
10.1016/j.amjsurg.2022.05.026
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The main aim of this study was to investigate the prevalence and prognostic value of preoperative diabetes mellitus (DM) in patients with non-functional pancreatic neuroendocrine neoplasms (NF-PNENs). Methods: Data were retrospectively collected from 190 patients with NF-PNENs from January 2009 to December 2019 in a single center. Results: The prevalence of longstanding DM, new-onset DM and impaired fasting glucose (IFG) was 11.6% (22/ 190), 8.4% (16/190), and 25.8% (49/190), respectively. Regression analysis showed that tumor size, tumor grade and lymph node metastasis were risk factors for new-onset DM and IFG. Multivariate survival analysis demonstrated preoperative new-onset DM (hazard ratio [HR], 4.33; P = 0.009) and IFG (HR, 4.53; P = 0.027) as independent predictors of poor recurrence-free survival (RFS) in patients with NF-PNENs. Conclusion: Preoperative new-onset DM and IFG are associated with aggressive tumor behavior and poor RFS in patients with NF-PNENs.
引用
收藏
页码:1162 / 1167
页数:6
相关论文
共 50 条
  • [21] Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality
    Junjun Wu
    Chi Sun
    Enliang Li
    Jiakun Wang
    Xianping He
    Rongfa Yuan
    Chenghao Yi
    Wenjun Liao
    Linquan Wu
    BMC Cancer, 19
  • [22] Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality
    Wu, Junjun
    Sun, Chi
    Li, Enliang
    Wang, Jiakun
    He, Xianping
    Yuan, Rongfa
    Yi, Chenghao
    Liao, Wenjun
    Wu, Linquan
    BMC CANCER, 2019, 19 (1)
  • [23] Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)
    Jin, Kaizhou
    Xu, Jin
    Chen, Jie
    Chen, Minhu
    Chen, Rufu
    Chen, Ye
    Chen, Zhiyu
    Cheng, Bin
    Chi, Yihebali
    Feng, Shi-Ting
    Fu, Deliang
    Hou, Baohua
    Huang, Dan
    Huang, Heguang
    Huang, Qiang
    Li, Jie
    Li, Ying
    Liang, Houjie
    Lin, Rong
    Liu, An'an
    Liu, Jixi
    Liu, Xubao
    Lu, Ming
    Lu, Jie
    Mai, Gang
    Ni, Quanxing
    Qiu, Meng
    Shao, Chenghao
    Shen, Baiyong
    Sheng, Weiqi
    Sun, Jian
    Tan, Chunlu
    Tan, Huangying
    Tang, Qiyun
    Tang, Yingmei
    Tian, Xiaodong
    Tong, Danian
    Wang, Xiaohong
    Wang, Jian
    Wang, Jie
    Wang, Wei
    Wang, Wei
    Wang, Yu
    Wu, Zheng
    Xue, Ling
    Yan, Qiang
    Yang, Ning
    Yang, Yinmo
    Yang, Zhiying
    Yin, Xiaoyi
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (05) : 1991 - 2000
  • [24] Compare the optimal TNM staging of resectable functional and non-functional pancreatic neuroendocrine tumors
    Xie, Z.
    Wang, Z.
    Cao, D.
    Ke, N.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 149 - 149
  • [25] Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system?
    Yang, Min
    Ke, Neng-Wen
    Zhang, Yi
    Tan, Chun-Lu
    Tian, Bo-Le
    Liu, Xu-Bao
    Huang, Wei
    Nunes, Quentin
    Sutton, Robert
    ONCOTARGET, 2017, 8 (47) : 82784 - 82795
  • [26] The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms
    Chen, Zhijiang
    Lin, Shizhao
    Liang, Feihong
    Hou, Zelin
    Yang, Yuanyuan
    Huang, Heguang
    Pan, Yu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [27] Management of Functional Pancreatic Neuroendocrine Neoplasms
    Ludovica Magi
    Matteo Marasco
    Maria Rinzivillo
    Antongiulio Faggiano
    Francesco Panzuto
    Current Treatment Options in Oncology, 2023, 24 : 725 - 741
  • [28] Management of Functional Pancreatic Neuroendocrine Neoplasms
    Magi, Ludovica
    Marasco, Matteo
    Rinzivillo, Maria
    Faggiano, Antongiulio
    Panzuto, Francesco
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (07) : 725 - 741
  • [29] Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors
    Paloma Cejas
    Yotam Drier
    Koen M. A. Dreijerink
    Lodewijk A. A. Brosens
    Vikram Deshpande
    Charles B. Epstein
    Elfi B. Conemans
    Folkert H. M. Morsink
    Mindy K. Graham
    Gerlof D. Valk
    Menno R. Vriens
    Carlos Fernandez-del Castillo
    Cristina R. Ferrone
    Tomer Adar
    Michaela Bowden
    Holly J. Whitton
    Annacarolina Da Silva
    Alba Font-Tello
    Henry W. Long
    Elizabeth Gaskell
    Noam Shoresh
    Christopher M. Heaphy
    Ewa Sicinska
    Matthew H. Kulke
    Daniel C. Chung
    Bradley E. Bernstein
    Ramesh A. Shivdasani
    Nature Medicine, 2019, 25 : 1260 - 1265
  • [30] MRI-based radiomics approach for differentiation of hypovascular non-functional pancreatic neuroendocrine tumors and solid pseudopapillary neoplasms of the pancreas
    Tao Song
    Qian-Wen Zhang
    Shao-Feng Duan
    Yun Bian
    Qiang Hao
    Peng-Yi Xing
    Tie-Gong Wang
    Lu-Guang Chen
    Chao Ma
    Jian-Ping Lu
    BMC Medical Imaging, 21